Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
δ-Catenin, a member of the p120-catenin subfamily of armadillo proteins, reportedly increases during the late stage of prostate cancer.
|
29629558 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
δ-Catenin, a member of the p120-catenin subfamily of armadillo proteins, reportedly increases during the late stage of prostate cancer.
|
29629558 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
γ-Tocotrienol inhibits cell viability through suppression of β-catenin/Tcf signaling in human colon carcinoma HT-29 cells.
|
21852086 |
2012 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.
|
23555187 |
2013 |
Childhood Hepatocellular Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.
|
23555187 |
2013 |
Adult Hepatocellular Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.
|
23555187 |
2013 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin.
|
29555987 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin.
|
29555987 |
2018 |
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin.
|
29555987 |
2018 |
Congenital contractural arachnodactyly
|
0.040 |
Biomarker
|
disease |
BEFREE |
β-escin was a potent reverser of P-gp-dependent multidrug resistance, with said effect likely being achieved via inhibition of the GSK3β/β-catenin pathway and thus suggesting a promising strategy of developing combination drugs for CCA.
|
25632187 |
2015 |
Cholangiocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
|
25632187 |
2015 |
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
β-catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network.
|
20615089 |
2010 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
β-Arrestins (Arrb) participate in the regulation of multiple signaling pathways, including Wnt/β-catenin, the major actor in human colorectal cancer initiation.
|
22315403 |
2012 |
Malignant neoplasm of colon and/or rectum
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Arrestins (Arrb) participate in the regulation of multiple signaling pathways, including Wnt/β-catenin, the major actor in human colorectal cancer initiation.
|
22315403 |
2012 |
cervical cancer
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
α-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and β-catenin stabilization in cervical cancer.
|
27065319 |
2016 |
Malignant tumor of cervix
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
α-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and β-catenin stabilization in cervical cancer.
|
27065319 |
2016 |
Cervix carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
α-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and β-catenin stabilization in cervical cancer.
|
27065319 |
2016 |
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
[The specific features of the expression of E-cadherin and beta-catenin in adenomyosis].
|
19137776 |
2009 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 19
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
Cerebral Palsy
|
0.110 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
Severe intellectual disability
|
0.110 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
Dysarthria
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
Little's Disease
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
Lower limb hypertonia
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |
CATARACT 32, MULTIPLE TYPES
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
[Intraoperative echocardiographic assessment of left ventricular muscle volume changes after intracardiac operation under cardiopulmonary bypass].
|
2614104 |
1989 |